Senior Correspondent, London
Ben's Feed
Dec 11, 2014

GAVI alliance commits up to $300 million to buy Ebola vaccines

LONDON (Reuters) – GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines and was ready to begin procurement as soon as the World Health Organization recommends one for use.

As much as $90 million more could also be made available to help affected countries introduce the vaccines and to rebuild their health systems, it added.

Dec 11, 2014
Dec 11, 2014
Dec 11, 2014

One shot or two? Many questions unresolved in Ebola vaccine race

LONDON (Reuters) – Scientists racing to develop vaccines against Ebola are trying to determine whether they can best fight the disease with a single injection or with two, a calculation that could determine how quickly and effectively a program can be rolled out.

Administering two vaccines, one after the other, would almost certainly give far greater protection than a single shot against a deadly virus that has killed more than 6,000 people in West Africa this year.

Dec 10, 2014
Dec 10, 2014

Returns on pharmaceutical R&D improving as pipelines revive

LONDON (Reuters) – Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development (R&D) increasing for the first time since 2010.

Overall R&D returns have improved to 5.5 percent this year from 5.1 percent in 2013, reflecting a modest uptick in productivity in company labs, according to the latest annual survey of the industry by Deloitte released on Wednesday.

Dec 9, 2014
Dec 9, 2014
Dec 8, 2014
Dec 8, 2014

Pfizer bets on gene therapy as technology comes of age

LONDON, Dec 8 (Reuters) – Pfizer Inc is moving into
the gene therapy space in the latest sign that the technology
for fixing faulty genes may finally be ready for prime time,
following earlier setbacks.

The U.S. drugmaker said on Monday it was establishing a gene
therapy platform to study potential treatments, led by a top UK
expert, and had struck a deal with privately owned U.S. biotech
firm Spark Therapeutics to develop a treatment for haemophilia.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben